SCHEMBL12433869

SCHEMBL12433869

Cc1cn(-c2cc(C(=O)Nc3ccc(C)c(NC(=O)c4csc5c(NC6CCCC6)ncnc45)c3)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.57
KDM4E B2RXH2 1/20 0.55
POLB P06746 1/20 0.55
RECQL P46063 1/20 0.55
ABL1 P00519 5/20 0.53
SRC P12931 1/20 0.53
MAPT P10636 1/20 0.52
BCR P11274 3/20 0.52
BRAF P15056 4/20 0.51
EPHB2 P29323 1/20 0.48
RAF1 P04049 1/20 0.47
HCK P08631 1/20 0.47
NR2C2 P49116 1/20 0.47
BTK Q06187 1/20 0.47
DDR1 Q08345 2/20 0.45
DDR2 Q16832 2/20 0.45
NTRK1 P04629 1/20 0.45
NTRK3 Q16288 1/20 0.45
NTRK2 Q16620 1/20 0.45
MAP4K2 Q12851 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12432449 0.97 CSF1R (0.58) CSF1RKDM4EPOLBRECQLABL1
SCHEMBL14717773 0.94 CSF1R (0.55) CSF1RKDM4EPOLBRECQLABL1
SCHEMBL14717063 0.92 ABL1 (0.52) CSF1RKDM4EPOLBRECQLABL1
SCHEMBL14717736 0.91 ABL1 (0.53) CSF1RKDM4EPOLBRECQLABL1
SCHEMBL12433475 0.90 ABL1 (0.63) ABL1SRCBCRBRAFEPHB2
SCHEMBL12433483 0.90 CSF1R (0.62) CSF1RKDM4EPOLBRECQLABL1
SCHEMBL2317353 0.90 ABL1 (0.51) CSF1RKDM4EPOLBRECQLABL1
SCHEMBL14110085 0.90 ABL1 (0.56) CSF1RKDM4EPOLBRECQLABL1
SCHEMBL14717859 0.89 ABL1 (0.55) CSF1RKDM4EPOLBRECQLABL1
SCHEMBL12433888 0.88 ABL1 (0.57) CSF1RKDM4EPOLBRECQLABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP claimed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US claimed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US claimed
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP disclosed
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed
WO-2011093684-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI HOLDINGS CO., LTD. (KR) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES CDK2, TK1, DTYMK CSF1R 3387/4885KDM4E 2448/4885POLB 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.